Global CDMO Footprint FIS operates with multi-site capabilities in Italy and commercial presence in the USA, Japan, China, and India, presenting a strong platform for international contract development and manufacturing opportunities across Custom, Generic, and Animal Health products.

Robust R&D to Scale With over 250 R&D specialists and integrated solutions from synthesis optimization to large-scale production, FIS can target clients seeking end-to-end development-to-commercialization support, leveraging its strong transition from R&D to manufacturing.

Sustainability & Safety A commitment to integrity, safety, quality, and people’s well-being signals a reliable partner for risk-averse manufacturers seeking compliant CDMO relationships with emphasis on responsible operations.

Private Equity Backing Control by Bain Capital and substantial funding imply potential liquidity for expansion, capacity upgrades, or strategic collaborations, making FIS attractive for co-investments, joint ventures, or capacity outsourcing deals.

Financials & Growth Signals Revenue scale indicates a mid-market player with room for growth; prospects include expanding manufacturing capacity, entering new therapeutic areas, or tiered service offerings to capture more generic and animal health API demand.